Moreover, KRAS-mutant lung adenocarcinoma patients with dissemination limited to the skeletal system (n = 13) tended to have a shorter OS then those with KRAS-WT tumors (7.0 vs 10.2 months; p = 0.21, Supplemental Fig. 1). This evidence concerns the gene KRAS and lung adenocarcinoma.